Yang HC, et al. - Researchers sought to analyze if baseline anti-hepatitis B core antibody (anti-HBc) and HBV surface antibody (anti-HBs) levels could better speculate HBV reactivation in lymphoma patients. It was reported that low anti-HBs and high anti-HBc at baseline illustrated a prominent link with high risk of HBV reactivation after receiving rituximab-containing chemotherapy in these lymphoma patients. It would aid in optimizing preventive strategy, particularly in HBV-endemic regions with limited health resources.